MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Neuromelanin-MRI of substantia nigra subregions in Parkinson’s disease

L. Borellini, G. Franco, P. Trujillo, P. Summers, A. Di Fonzo, D.O. Claassen, A. Costa (Milan, Italy)

Meeting: 2016 International Congress

Abstract Number: 1315

Keywords: Magnetic resonance imaging(MRI), Neuromelanin, Substantia nigra pars compacta(SNpc)

Session Information

Date: Wednesday, June 22, 2016

Session Title: Parkinson's disease: Neuroimaging and neurophysiology

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To detect changes in the different subregions of the substantia nigra pars compacta (SNc) in patients with Parkinson’s disease (PD) and to correlate the results with clinical data.

Background: Reduced midbrain Neuromelanin (NM) in PD is attributed to loss of pigmented dopaminergic neurons localized especially to the SNc. Non-invasive Magnetic Resonance Imaging (MRI) markers of NM can quantify NM, and detect alterations to SNc-NM morphology, thus offering unique opportunities to link pathophysiologic and clinical progression.

Methods: We performed 3T NM-MRI measurements on 38 PD patients; 18 with less than 5 years from disease onset (age at examination 45-76 y; H&Y stage: 1-3), 20 with longer disease duration ranging from from 9-23 y (age at examination 48-78 y; H&Y stage: 1-4), and 20 age-matched healthy controls (aged 50-75 y). All subjects completed a neurological examination assessing motor and cognitive function (Montreal Cognitive Assessment (MoCA)). Circular ROIs were defined in the lateral, central and medial parts of the SN in three consecutive slices (caudal, intermediate, rostral). The contrast-to-noise ratio (CNR) between the each ROI and the cerebral crus was computed, where a lower CNR represents greater loss of NM. The Steel-Dwass test was used to compare the results between groups and the Spearman correlation coefficient was used to examine the correlations between imaging results and clinical data.

Results: Across all ROIs, the CNR values were found to be reduced in PD patients as compared with controls, and were lower in PD patients with longer disease duration. For all subjects, the CNR was higher in the caudal-medial subregion, and in PD patients, greater reductions in CNR were towards the rostral and lateral axes of the SN. A significant correlation between the CNR in the central SNc subregion and cognitive performances (MoCA scores), but not with motor performances, was detected.

Conclusions: Study results support that NM-MRI detected changes in PD patients. While this tool may provide useful diagnostic information to detect degeneration of dopaminergic neurons in SNc, these data suggest that NM changes appear early in the disease course. Clinical relationships between different subregions of SNc emphasize a positive association between the degeneration of its central portion and cognitive function in PD. This relationship needs to be examined prospectively.

To cite this abstract in AMA style:

L. Borellini, G. Franco, P. Trujillo, P. Summers, A. Di Fonzo, D.O. Claassen, A. Costa. Neuromelanin-MRI of substantia nigra subregions in Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/neuromelanin-mri-of-substantia-nigra-subregions-in-parkinsons-disease/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/neuromelanin-mri-of-substantia-nigra-subregions-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley